SCHEMBL450145

SCHEMBL450145

COC(=O)c1cc(-c2ccc(F)cc2)c2oc(C(C)(C)C)nc2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 2/20 0.41
SLC6A4 P31645 1/20 0.40
SLC6A3 Q01959 1/20 0.40
PTPN7 P35236 1/20 0.40
KDM4E B2RXH2 4/20 0.39
GRM2 Q14416 1/20 0.39
SMN1; SMN2 Q16637 5/20 0.38
RAB9A P51151 5/20 0.38
NPC1 O15118 4/20 0.38
CASP3 P42574 1/20 0.38
SENP8 Q96LD8 1/20 0.38
SENP7 Q9BQF6 1/20 0.38
SENP6 Q9GZR1 1/20 0.38
MAPK14 Q16539 3/20 0.37
MAPT P10636 5/20 0.37
HPGD P15428 3/20 0.37
ALDH1A1 P00352 2/20 0.37
HSD17B10 Q99714 2/20 0.37
ESR2 Q92731 1/20 0.37
MAP2K4 P45985 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL451479 0.87 GPR35 (0.41) GRM2RAB9ANPC1MAPK14MEN1
SCHEMBL454487 0.82 RAB9A (0.45) PTGS1SLC6A4SLC6A3PTPN7KDM4E
SCHEMBL454485 0.77 NOTUM (0.40) KDM4ESMN1; SMN2RAB9ANPC1MAPT
SCHEMBL455089 0.75 DGAT2 (0.43)
SCHEMBL455504 0.70 MAPK14 (0.40) PTGS1SLC6A4SLC6A3PTPN7KDM4E
SCHEMBL454330 0.68 RAB9A (0.45) GRM2RAB9ANPC1MAPK14MEN1
SCHEMBL462011 0.68 FPR2 (0.44) PTGS1SLC6A4SLC6A3PTPN7KDM4E
SCHEMBL5638115 0.68 MAPT (0.70) KDM4ESMN1; SMN2RAB9ANPC1MAPT
SCHEMBL452451 0.67 KDM4E (0.52) PTGS1SLC6A4SLC6A3KDM4ERAB9A
SCHEMBL4486670 0.67 KDM4E (0.57) PTGS1SLC6A4SLC6A3KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9238647-B2 P2X3 receptor antagonists for treatment of pain MERCK SHARP & DOHME CORP. (US) 2016-01-19 US disclosed
EP-2410857-B1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK SHARP & DOHME (US) 2014-01-29 EP disclosed
US-20120064181-A1 P2X3 Receptor Antagonists for Treatment of Pain MERCK SHARP & DOHME LLC 2012-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120064181-A1 P2X3 Receptor Antagonists for Treatment of Pain P2RX3, P2RX1, P2RX2 PTGS1 294/4885SLC6A4 603/4885SLC6A3 553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.